Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
The average time of dilation lasts three to eight hours
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Executes the first project for developing and manufacturing a novel anticancer mAb
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The facility will manufacture tablets, capsules, and injections for the oncology segment
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Subscribe To Our Newsletter & Stay Updated
